RIGL RIGEL PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended June 30, 2026, RIGEL PHARMACEUTICALS INC reported revenue of $78.7M (down 22.6% from a year earlier), net income of $17.3M and diluted EPS of $0.88; over the last four quarters revenue was $277M and net income $322M; for the fiscal year ended December 2025 revenue was $294M, up 64.1% on the year before.
RIGL annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $294M, gross profit n/a, operating income $125M, net income $367M (margin 124.7%), EPS $19.48
- Fiscal year ended Dec 2024: revenue $179M, gross profit n/a, operating income $24.2M, net income $17.5M (margin 9.8%), EPS $0.99
- Fiscal year ended Dec 2023: revenue $117M, gross profit n/a, operating income −$20.5M, net income −$25.1M (margin -21.5%), EPS −$1.44
- Fiscal year ended Dec 2022: revenue $120M, gross profit n/a, operating income −$55.6M, net income −$58.6M (margin -48.7%), EPS −$3.44
- Fiscal year ended Dec 2021: revenue $149M, gross profit n/a, operating income −$12.5M, net income −$17.9M (margin -12.0%), EPS −$0.11
RIGL quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $78.7M (down 22.6% year over year), net income $17.3M, EPS $0.88
- Quarter ended Mar 31, 2026: revenue $58.8M (up 10.3% year over year), net income $8.65M, EPS $0.44
- Quarter ended Dec 31, 2025 (from the annual report): revenue $69.8M (up 21.2% year over year), net income $268M, EPS $14.11
- Quarter ended Sep 30, 2025: revenue $69.5M (up 25.6% year over year), net income $27.9M, EPS $1.46
- Quarter ended Jun 30, 2025: revenue $102M (up 176.0% year over year), net income $59.6M, EPS $3.28
- Quarter ended Mar 31, 2025: revenue $53.3M (up 80.6% year over year), net income $11.4M, EPS $0.63
- Quarter ended Dec 31, 2024 (from the annual report): revenue $57.6M (up 60.9% year over year), net income $14.3M, EPS $0.82
- Quarter ended Sep 30, 2024: revenue $55.3M (up 96.6% year over year), net income $12.4M, EPS $0.70
- Quarter ended Jun 30, 2024: revenue $36.8M (up 37.0% year over year), net income −$1.03M, EPS −$0.06
- Quarter ended Mar 31, 2024: revenue $29.5M (up 13.3% year over year), net income −$8.25M, EPS −$0.47
- Quarter ended Dec 31, 2023 (from the annual report): revenue $35.8M (down 30.2% year over year), net income $737K, EPS −$0.65
- Quarter ended Sep 30, 2023: revenue $28.1M (up 25.5% year over year), net income −$5.69M, EPS −$0.33
- Quarter ended Jun 30, 2023: revenue $26.9M (down 9.8% year over year), net income −$6.60M, EPS −$0.38
- Quarter ended Mar 31, 2023: revenue $26.1M (up 55.8% year over year), net income −$13.5M, EPS −$0.08
- Quarter ended Dec 31, 2022 (from the annual report): revenue $51.3M (up 151.3% year over year), net income $1.40M, EPS −$3.09
- Quarter ended Sep 30, 2022: revenue $22.4M (up 4.0% year over year), net income −$19.0M, EPS −$0.11
- Quarter ended Jun 30, 2022: revenue $29.8M (up 13.5% year over year), net income −$13.5M, EPS −$0.08
- Quarter ended Mar 31, 2022: revenue $16.7M (down 79.3% year over year), net income −$27.4M, EPS −$0.16
- Quarter ended Dec 31, 2021 (from the annual report): revenue $20.4M, net income −$22.6M, EPS −$0.13
- Quarter ended Sep 30, 2021: revenue $21.5M, net income −$21.0M, EPS −$0.12
RIGL cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow $75.7M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow $31.5M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$5.74M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$73.8M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow $5.88M, share buybacks n/a
RIGL balance sheet
- Jun 30, 2026: cash $60.8M, total assets $521M, total liabilities $95.6M, shareholders' equity $425M
- Mar 31, 2026: cash $24.4M, total assets $505M, total liabilities $105M, shareholders' equity $400M
- Dec 31, 2025: cash $40.6M, total assets $514M, total liabilities $122M, shareholders' equity $391M
- Sep 30, 2025: cash $48.5M, total assets $243M, total liabilities $125M, shareholders' equity $118M
- Jun 30, 2025: cash $53.4M, total assets $207M, total liabilities $125M, shareholders' equity $81.9M
- Mar 31, 2025: cash $45.7M, total assets $176M, total liabilities $157M, shareholders' equity $18.6M
- Dec 31, 2024: cash $56.7M, total assets $164M, total liabilities $161M, shareholders' equity $3.29M
- Sep 30, 2024: cash $51.7M, total assets $139M, total liabilities $154M, shareholders' equity −$14.6M
What is RIGL's revenue?
RIGEL PHARMACEUTICALS INC reported $277M of revenue over its last four quarters, through June 30, 2026.
Is RIGL profitable?
Yes. RIGEL PHARMACEUTICALS INC earned $322M over the last four quarters.
What is RIGL's EPS?
Diluted earnings per share over the last four quarters were $16.89; $0.88 in the latest quarter.